This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Trovagene, Inc., a molecular diagnostic company, focuses on the development and commercialization of proprietary urine-based cell-free molecular diagnostic technology for use in disease detection and monitoring across various medical disciplines.View TROV
TrovaGene, Inc. - TROV - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates TrovaGene, Inc. as a
Sell with a ratings score of D-.
Report Snippet: We rate TROVAGENE INC (TROV) a SELL. This is driven by several weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow, feeble growth in its earnings per share and generally disappointing historical performance in the stock itself.